ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japan faces short supply of coronavirus drug remdesivir

Gilead Sciences to distribute enough to cover 140,000 patients worldwide

Some hope Gilead Sciences' Ebola drug remdesivir, left, can prove effective against the novel coronavirus. (Nikkei montage of Reuters/U.S. National Institute of Allergy and Infectious Diseases images)

TOKYO -- Japan will not be able to receive a stable supply of promising coronavirus therapy remdesivir from its U.S. developer to treat all patients in need, Nikkei learned Friday.

Remdesivir's developer, Gilead Sciences, plans to distribute enough doses to cover 140,000 patients worldwide, but Japan will receive only a small portion of the supply. 

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more